Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATRN 119 (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Appendiceal cancer; Colon cancer; Colorectal cancer; Duodenal cancer; Endometrial cancer; Fallopian tube cancer; Male breast cancer; Merkel cell carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms ABOYA-119
  • Sponsors Aprea Therapeutics; Atrin Pharmaceuticals

Most Recent Events

  • 25 Mar 2025 According to an Aprea Therapeutics media release, patients are currently being enrolled at Dose Level 7, with both 1100 mg once daily and 550 mg twice daily doses being evaluated independently and in parallel.
  • 25 Mar 2025 According to an Aprea Therapeutics media release, twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119 and company plans to complete dose escalation H2 2025
  • 26 Feb 2025 Planned End Date changed from 1 Jun 2025 to 1 Feb 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top